3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
17
Colorectal Neoplasms
13
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
4
Neoplasm Metastasis
4
Skin Neoplasms
3
Lung Neoplasms
3
Gastrointestinal Neoplasms
3
Rectal Neoplasms
2
Digestive System Neoplasms
2
Colonic Neoplasms
2
Solid Tumors Harboring a BRAF V600 Mutation
1
Solid Tumors
1
Skin Diseases
1
Rectal Diseases
1
Pancreatic Neoplasms
1
Neurofibromatosis 1
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Diseases
1
Colonic Diseases
1
Brain Neoplasms
1
Interventions
Gemcitabine
205
130-nm albumin-bound paclitaxel
84
Albumin-Bound Paclitaxel
57
pembrolizumab
43
Fluorouracil
41
Leucovorin
34
Oxaliplatin
33
Capecitabine
25
Nivolumab
22
Irinotecan
19
Bevacizumab
17
Paclitaxel
16
Cyclophosphamide
15
Cetuximab
15
Taxes
13
Erlotinib Hydrochloride
13
Drug Therapy
13
Carboplatin
12
irinotecan sucrosofate
11
Injections
10
Cisplatin
9
fludarabine
8
ALT-803
8
spartalizumab
7
olaparib
7
avelumab
7
Pemetrexed
7
Docetaxel
7
ruxolitinib
6
TH 302
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pancreatic Neoplasms
×
encorafenib
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled